Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

7 mins

Kateki Vinod, AGS 2022: Head to Head Surgical Trials: Tubes and Trabs

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Apr 11th 2022

Dr Kateki Vinod (New York Eye and Ear Infirmary of Mount Sinai, New York, NY, USA) gives us a run down of the tube versus trabeculectomy (TVT) study and the primary tube versus trabeculectomy (PTVT) study and discusses the results and take home messages.

The presentation entitled ‘ Head to Head Surgical Trials: Tubes and Trabs’ was presented at the 2022 American Glaucoma Society Annual Meeting, March 03-06, 2022

Questions:

  1. Can you tell us about the TVT and the PTVT study and  what they have taught us about the relative merits of trabeculectomy or tube shunts?  (00:18)
  2. What clinical trials have been initiated since these landmark studies? (04:14)
  3. What questions remain unanswered and what future studies are planned?(05:57)

Disclosures: Kateki Vinod has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup